GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (NYSE:HLN) » Definitions » Return-on-Tangible-Asset

Haleon (Haleon) Return-on-Tangible-Asset : 23.59% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Haleon Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Haleon's annualized Net Income for the quarter that ended in Mar. 2024 was $2,150 Mil. Haleon's average total tangible assets for the quarter that ended in Mar. 2024 was $9,114 Mil. Therefore, Haleon's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 23.59%.

The historical rank and industry rank for Haleon's Return-on-Tangible-Asset or its related term are showing as below:

HLN' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 8.51   Med: 15.55   Max: 19.62
Current: 16.19

During the past 5 years, Haleon's highest Return-on-Tangible-Asset was 19.62%. The lowest was 8.51%. And the median was 15.55%.

HLN's Return-on-Tangible-Asset is ranked better than
92.14% of 1081 companies
in the Drug Manufacturers industry
Industry Median: 1.85 vs HLN: 16.19

Haleon Return-on-Tangible-Asset Historical Data

The historical data trend for Haleon's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Return-on-Tangible-Asset Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
8.51 15.88 19.52 14.82 15.73

Haleon Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.30 18.37 22.05 -0.17 23.59

Competitive Comparison of Haleon's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haleon's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haleon's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Haleon's Return-on-Tangible-Asset falls into.



Haleon Return-on-Tangible-Asset Calculation

Haleon's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=1327.848/( (7769.793+9113.924)/ 2 )
=1327.848/8441.8585
=15.73 %

Haleon's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=2149.936/( (9113.924+0)/ 1 )
=2149.936/9113.924
=23.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Haleon  (NYSE:HLN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Haleon Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Haleon's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Haleon (Haleon) Business Description

Traded in Other Exchanges
Address
The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.